Janssen Enters Into Agreement With Sanofi to Advance Potential First-In-Class Vaccine Program
October 04, 2023
October 04, 2023
TITUSVILLE, New Jersey, Oct. 4 -- The Janssen Pharmaceutical Companies of Johnson and Johnson issued the following news release on Oct. 3, 2023:
Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson Company, today announced a development and commercialization agreement with Sanofi for Janssen's extraintestinal pathogenic Escherichia coli (ExPEC) investigational vaccine program. The lead vaccine candidate is currently being evaluated in the Phase 3 E.mbrace study for the p . . .
Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson Company, today announced a development and commercialization agreement with Sanofi for Janssen's extraintestinal pathogenic Escherichia coli (ExPEC) investigational vaccine program. The lead vaccine candidate is currently being evaluated in the Phase 3 E.mbrace study for the p . . .